Analysis of Long-term Results of Our Combination Therapy for Squamous Cell Cancer of the Maxillary Sinus

• Published in: Acta oto-laryngologica Vol. 118; no. 537; pp. 57 - 66
• Main Author: Konno, Kazuo Ishikawa, Nobuhisa Terada, Tsutomu Numata, Hiroshi Nagata, Yoshitaka Okamoto, Akiyoshi
• Format: Journal Article
• Language: English
• Published: Norway Informa UK Ltd 1998; Taylor & Francis
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - therapy; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Maxillary Sinus Neoplasms - mortality; Maxillary Sinus Neoplasms - therapy; Middle Aged; Radiotherapy Dosage; Survival Rate; Time Factors; Treatment Outcome
• ISSN: 0001-6489; 0365-5237; 1651-2251
• DOI: 10.1080/00016489850182378-1

Seventy-four patients between 1971 and 1982 in Period I and 32 patients between 1982 and 1987 in Period II with maxillary sinus squamous cell cancer were treated by combination therapy consisting of preoperative LINAC X-ray irradiation with 5-flourouracil intra-arterial chemotherapy followed by maxillectomy and primary reconstruction. In Period II, 21 patients received preoperative cisplatinum (CPPP) microcapsule chemoembolization and pepleomycin (PEP) i.m. and/or postoperative CDDP i.v. with PEP i.m. in addition to the combination therapy administered in Period I depending on systemic conditions, tumor stage and histopathological type. Five and 10-year crude survival rates were 68.9% and 55.4%, respectively, for Period I and 71.9% and 56.3% for Period II, with no significant difference between the two trials. In 21 selected patients in Period II, who had additional chemotherapy with preoperative CDDP chemoembolization and/or postoperative i.v. infusion of CDDP with pepleomycin i.m., 5 and 10-year survival rates were 85.7% and 61.9%, respectively.